A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects with Advanced Head and Neck Squamous Cell Carcinoma
To determine the safety and tolerability of ACP-196 (study drug) in combination with keytruda in patients with advanced head and neck squamous cell carcinoma.
Head and neck squamous cell carcinoma (HNSCC)
1. Male or female age 18 or older
2. Confirmed diagnosis of recurrent, metastatic, or unresectable HNSCC
3. Disease progression after either a) platinum-based chemotherapy for metastatic disease or b) recurrence within 6 months of platinum-based neoadjuvant or adjuvant therapy
4. Ability to swallow capsules
5. Other criteria apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
Treatment can continue for up to 52 weeks for subjects who are tolerating therapy
and have not developed progressive disease. After discontinuing study therapy, subjects will be contacted by phone about every 3 months.
Knight Clinical Trials Information Line
Acerta Pharma BV